Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 29 tags : Covid save search
Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC
Published: 2021-03-29 (Crawled : 19:00) - biospace.com/
GRTS | $0.8129 10.06% 9.92% 1.8M
|
Health Technology
|
| O: 0.09%
H: 2.0%
C: -10.27%
covid phase 1 vaccine phase 3 phase 2
COVID-19 Billing: 4 ways the pandemic is reshaping healthcare payments
Published: 2021-03-29 (Crawled : 18:00) - multiplan.us
MPLN | $0.5818 3.86% 0.0% 3.4M
|
Finance
|
| O: 0.51%
H: 0.17%
C: -2.54%
covid covid-19
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
Published: 2021-03-29 (Crawled : 14:39) - biospace.com/
XGN | $1.38 -1.43% -2.19% 2.6K
|
Health Services
|
| O: -1.65%
H: 6.97%
C: 2.66%
covid disease injection infections
Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 57.11%
H: 32.85%
C: -1.68%
covid results topline lenzilumab phase 3 conference
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.82%
H: 1.18%
C: 0.88%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.63%
C: 0.91%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.46%
H: 1.02%
C: -4.73%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.57%
covid phase 2 risk positive topline biotech technology iot trial
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
Published: 2021-03-29 (Crawled : 13:00) - irdirect.net
DYAI 4 | $1.5 0.67% 1.97% 3.4K
|
Health Technology
|
| O: 1.87%
H: 0.92%
C: -3.12%
ISDR | $11.65 -1.69% 0.0% 390
|
Technology Services
|
| O: 0.0%
H: 3.91%
C: -2.28%
covid vaccine trial covid-19
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Published: 2021-03-29 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 57.11%
H: 32.85%
C: -1.68%
covid positive results topline phase 3 lenzilumab
Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
Published: 2021-03-29 (Crawled : 13:00) - globenewswire.com
OCGN | News 4 | $1.18 -5.6% -6.84% 7.2M
|
Health Technology
|
| O: -2.1%
H: 0.29%
C: -6.88%
covid vaccine
CVS Health to Administer No-Cost COVID-19 Vaccines at Select CVS Pharmacy Locations in West Virginia
Published: 2021-03-29 (Crawled : 12:00) - prnewswire.com
CVS | $67.77 -1.07% 0.06% 6.7M
|
Retail Trade
|
| O: -0.34%
H: 1.55%
C: 0.79%
covid vaccine
CVS Health to Administer No-Cost COVID-19 Vaccines at Select CVS Pharmacy Locations in Washington
Published: 2021-03-29 (Crawled : 12:00) - prnewswire.com
CVS | $67.77 -1.07% 0.06% 6.7M
|
Retail Trade
|
| O: -0.34%
H: 1.55%
C: 0.79%
covid vaccine health covid-19
Global Acetic Acid Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Market Forecasts, Analysis 2021-2025 | SpendEdge
Published: 2021-03-29 (Crawled : 10:41) - prnewswire.com
LYB | $100.78 0.23% 0.0% 1.1M
|
Process Industries
|
| O: -0.18%
H: 3.13%
C: -1.09%
covid
QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio
Published: 2021-03-29 (Crawled : 10:41) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.16%
H: 0.14%
C: -0.6%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -1.16%
H: 0.14%
C: -0.6%
covid fda test merge authorized covid-19 emergency use authorization
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
Published: 2021-03-29 (Crawled : 10:41) - biospace.com/
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: -0.67%
H: 1.95%
C: 1.35%
covid acquisition vaccine
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.